Monograph Details
|
|
Central Nervous System
> Insomnia
|
|
HALCION |
| Manufacturer |
|
Pfizer Labs |
| Legal Classification |
|
CIV |
| Pharmacological Class |
|
Benzodiazepine. |
| Generic Name |
|
Triazolam 0.125mg, 0.25mg+; tabs; +scored. |
| Indications |
|
Short-term (7–10 days) treatment of insomnia. |
| Children |
|
<18yrs: not recommended. |
| Adults |
|
≥18yrs: 0.125–0.25mg at bedtime; max 0.5mg. Elderly or debilitated: initially 0.125mg, max 0.25mg. Max 1 month/Rx. |
| Contraindications |
|
Concomitant ketoconazole, itraconazole, nefazodone, other potent CYP3A inhibitors. Pregnancy (Cat.X). |
| Precautions |
|
Overdosage may occur at 2mg. Suicidal tendencies. Depression. Pulmonary, renal, or hepatic disease. Sleep apnea. Drug or alcohol abuse. Reevaluate if used ≥2–3 weeks. Avoid abrupt cessation. Discontinue if excitement or daytime anxiety occurs. Nursing mothers: not recommended. |
| Interactions |
|
See Contraindications; other azole antifungals: not recommended. Potentiates CNS depression with alcohol, other CNS depressants. Potentiated by ranitidine, grapefruit juice, isoniazid, oral contraceptives. Reduce triazolam dose with cimetidine, erythromycin, other macrolides. Caution with fluvoxamine, diltiazem, verapamil, sertraline, paroxetine, ergotamine, cyclosporine, amiodarone, nicardipine, nifedipine, others metabolized by CYP3A. |
| Adverse Reactions |
|
CNS depression, complex sleep-related behaviors (eg, sleep-driving), ataxia, headache, nausea, paradoxical excitement, anxiety, worsening of insomnia, abnormal behavior, amnesia; anaphylaxis, angioedema. |
| How Supplied |
|
Tabs—10, 500 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
